HILTON HEAD, S.C., June 16, 2026. Ailethea Inc., a pioneering AI-native technology platform and operational company infrastructure, today announced the formal addition of Adroit-Metis as a premier venture within its corporate portfolio. Under the terms of the integration, Adroit-Metis’s regulatory advisory practice and its Smarter PATH™ Workflows are being built on Ailethea’s proprietary multi-classifier artificial intelligence engine, TRIAD-AI. Ailethea operates an advanced business acceleration ecosystem that provides end-to-end infrastructure, capital, and operational suites, spanning finance, law, RevOps, and compliance validation, to companies delivering material benefit to People, Animals, and the Planet.
The inclusion of Adroit-Metis aligns with Ailethea’s People pillar by advancing drug manufacturing and safety for the patients who depend on the highest-risk therapies, an area that operates under complex regulatory frameworks and intensive documentation requirements.
Adroit-Metis addresses some of the most demanding and regulated operations in pharmaceuticals from the first investor dollar to the last post-market commitment through their three Smarter PATH™ workflows: Smarter PATH™ to Approval, Smarter PATH™ to Investing, and Smarter PATH™ to REMS.
“Building Smarter PATH™ on TRIAD-AI lets us extend that same human-centered judgment to far more programs and far more patients, without diluting the rigor that Adroit-Metis demands.”
Michelleanne Bradley, Co-Founder of Adroit-Metis
By pairing Adroit-Metis’s expertise with Ailethea’s TRIAD-AI engine, Smarter PATH™ brings predictive structure and automated document generation to processes that have long depended on manual curation and guesses, while keeping experienced regulatory professionals in control of every risk decision. The approach reflects the philosophy that has defined Adroit-Metis from the start: patients remain at the center of all risk decisions because, ultimately, we are all patients.
“Most high-impact therapies do not stall because the science is wrong. They stall because the safety and compliance work around them is slow, manual, and unforgiving,” said Ramon Dempers, Co-Founder and Chief Visionary Officer of Ailethea. “With Adroit-Metis, we are bringing deep, patient-centered expertise onto our TRIAD-AI framework. We are not merely providing passive investment. We are supplying the intelligence layer and operating system that turns hard-won human judgment into durable infrastructure.”
The collaboration follows a phased roadmap powered by Ailethea’s continuous data flywheel. Phase 1 focuses on automated REMS document generation and submission support built on TRIAD-AI. Phase 2 will introduce ongoing assessment and reporting workflows that keep programs current as they mature. Phase 3 will deliver continuous monitoring against evolving FDA expectations, ensuring that every REMS program remains audit-ready across its full lifecycle.
“Our work is always patient-focused,” said Michelleanne Bradley, Co-Founder of Adroit-Metis. “Building Smarter PATH™ on TRIAD-AI lets us extend that same human-centered judgment to far more programs and far more patients, without diluting the rigor that Adroit-Metis demands. With Ailethea, we are scaling the care and the process.”
